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Figure S1. Functional analysis of human peripheral blood mononuclear cells. 
Cells were obtained from healthy control subjects (WT) and from patients with type 1 
diabetes carrying wild type SIRT1 (DM1) or the L107P mutation (SIRT). (A), protein 
analysis at single cell level determined by FACS and (B), mRNA transcription 
analysis assessed by quantitative RT-PCR, following anti-CD3/TPA stimulation of 
purified CD4+ Th cells. n=3 for each of the three groups. 
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EXOME SEQUENCING
p845: whole exome sequencing
Two selected position with SNPs that are present only in 2 affected patients
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33 2 chr10 72300885 C - - - - - - - - - - Y C/T 17 5 11 Y C/T 19 11 6 - - - - - - - - - - KIAA1274 NM_014431 72300858 72300998 chr10 +
33 2 chr10 73521578 G - - - - - - - - - - A A 8 0 7 R G/A 23 18 5 - - - - - - - - - - C10orf54 NM_022153 73521355 73521783 chr10 -
Figure S2. Genome-wide linkage analysis and analysis of the KIAA1274 variant. 
(A) The LOD score in genome-wide linkage analysis using 811 microsatellite markers 
(ABI prism linkage mapping set HD5 v2.5) covering 22 chromosomes. Each box 
represents a chromosome. The x axis gives the genetic distance in cM, and the y 
axis gives the LOD scores. Significance in whole genome microsatellite mapping  
LOD >2.2. Chromosome 10 (LOD 4.0 between D10S210 and D10S537) 
Chromosome 22 (LOD 2.2). (B) Roman numerals refer to the individuals identified in 
Figure 1.  
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DIRECT SEQUENCING
 KIAA1274= Paladin  (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731165/pdf/pone.0006871.pdf)          Exon 16  
Affected  IV-2 heterozygous C/T *   *(known SNP rs117803924 c.2217c>t   non synonymous change p.R646W)
  III-1 heterozygous C/T
  III-4 homozygous C
  IV-9 homozygous C
  IV-1 homozygous C
Non affected:  III-3 heterozygous C/T
  IV-4 homozygous C
  IV-5 homozygous C
  IV-8 homozygous C
Controls  unaffected (n=50) 20/50 C/T 30/50 C Ashkenazy Jews (n=20) 12/20 C/T  8/20 C T1DM white (N=50)  23 C/T 27 C
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Figure S3. Measurement of SIRT1-L107P deacetylase activity and detection of 
SIRT1 and SIRT1-L107P protein-protein interactions 
(A) Equal amounts of Flag-tagged wild-type SIRT1 (diamonds) or Flag-tagged 
SIRT1-L107P (squares) were produced and purified from 293T cells. Enzymatic 
activity was assessed using the BIOMOL Fluor de Lys kit at several time intervals (0, 
1, 2, 3 hours). (n=3) All data are presented as mean ± SEM. (B) Identification of the 
top SIRT1 interacting partners via LC-MS/MS. (C) Comparison of SIRT1- Wt and 
L107P interactions with DBC1 and c-Jun in 293T cells. (D) Comparison of SIRT1- Wt 
and L107P interactions with DDX56 in 3T3 cells 
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5Figure S4. Western blots of MIN6 cells overexpressing Flag tagged wt SIRT1 or 
L107P SIRT1 and Impaired insulin sensitivity in human skeletal myotubes 
overexpressing L107P SIRT1.
(A) Protein extracts of MIN6 empty, MIN6 wt SIRT1, MIN6 L107P SIRT1, wt Mouse 
embryo fibroblasts (MEF) and SIRT1 deficient MEFs were analysed by Western 
blotting using an anti-mouse SIRT1, an anti-human SIRT1, and an anti-FLAG 
antibody. Equal protein loading of the blots was verified by Ponceau staining. Note 
that the anti-mouse SIRT1 antibody crossreacts with the FLAG-tagged human 
SIRT1. Taq Man real time PCR data with primers specific for human SIRT1 further 
confirmed that the SIRT expression level was comparable between wt and L107P 
overexpressing cells. (B) Measurement of insulin stimulated glucose uptake of 
cultured human skeletal myotubes obtained from biopsies of the vastus lateralis 
muscle of non-transduced healthy individuals, and those transduced with wild type 
(wt) and L107P SIRT1 (n=3). All data are presented as mean ± SEM. 
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6Table S1: Pattern of hybridization of DBQ1 sequence-specific probes. The “+” sign 
indicates hybridization of the probe to the sequence 
DQB1 
Allele 
AD01
27 
AD01
28 
AD01
29 
AD01
30 
AD01
31 
AD01
32 
AD01
50 
AD01
51 
AD01
52 
AD01
53 
AD01
54 
AD01
55
02   +   +       
0301,0309   +  +    +    
0302,0307   + +         
0303, 
0306, 0310 +
      
+
   
0304   + + +        
03051   + +    +  +   
03052   + +    +     
04   +     +  +   
05011   +     +   +  
05012, 
0503 
  +     +     
0502, 0504   +     +     
0601   +    +      
0602, 
0611, 
0613, 
0615, 
06042 
+ +
         
0603, 
0607, 
0608, 
0614, 
+ + +
         
0604, 0617  + +          
0610 +  +         + 
Subject             
IV-1   ᅛ ᅛ ᅛ ᅛ ᅛ
III-1   ᅛ ᅛ    ᅛ ᅛ
III-3   ᅛ ᅛ    ᅛ ᅛ
III-4   ᅛ ᅛ ᅛ    ᅛ    
IV-9   ᅛ ᅛ ᅛ    ᅛ ᅛ
IV-5   ᅛ ᅛ     ᅛ ᅛ
III-9 ᅛ ᅛ ᅛ ᅛ
CONTROL ᅛ ᅛ ᅛ    ᅛ    
7SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Mutation analysis.  
Genomic DNA was extracted from peripheral blood leukocytes. DNA from 100 
unrelated individuals (80 Caucasian, 8 of whom from Turkey; 10 Asian; 10 Blacks, 2 
of whom from Central America and 2 Hispanic) was used as control for 
polymorphisms. HLA-DQB1 analysis was performed using the DELFIA Hybridization 
Assay (Wallac Oy, Turku, Finland) and Microsatellite analysis was performed using 
the ABI Prism Linkage mapping set version 2.5 (811 markers, Applied Biosystems). 
Haplotypes were reconstructed by using the GENEHUNTER package (Version 1.2). 
The disease gene frequency in the general population was set at 0.0001. Two-point 
and multipoint linkage analyses were performed by GENEHUNTER by using the 
affected-only allele-sharing method. SLink simulations were done by the FASTLINK 
package. For direct sequencing, the coding regions of SIRT1 (NC_000010.9 region 
69314433..69348149), TCF7L2 (NC_000010.9), IRS2 (NC_000013.9) and SOCS2 
(NC_000012.10) were amplified and the PCR products were sequenced using the 
Big Dye Terminator Cycle Sequencing Kit and analyzed on an ABI Prism 310 Genetic 
Analyzer (Applied Biosystems). Sanger sequencing for the validation of the human 
exome resequencing of SNP rs.117803924 (c.[2217C>T], p.Arg646Trp) in exon 16 of 
KIAA1274 (Paladin NM_014431 region 72300858..72300998) gene present in at 
least two family members, was performed in affected (n=5) and non-affected (n=4) 
family members, normal individuals (n=50), ethnic matched controls (Ashkenazi Jews 
n=20) and Type 1 diabetic patients (white n=50). Nucleotide and amino acid 
exchanges are named according to http://www.hgvs.org/mutnomen/. 
To confirm that the SIRT1 mutation is causative we also performed whole-
exome sequencing. The all exome enriched library was produced using the SOLiD 
Fragment Library Construction kit (Applied Biosystems p/n 4443471) and the 
SureSelect Human exome kit (Agilent p/n G3362B). The exome design targets all 
human exon regions, totaling approximately 38 Mb. 3 ȝg of genomic DNA was 
fragmented to a size range of 100–150 bp with the use of a Covaris Instrument S2 
(Covaris) and analyzed on an Agilent Bioanalyzer 2100 DNA Chip 7500. Fragments 
were end-repaired using polishing enzymes and ligated with truncated adaptors in 
presence of T4 DNA Ligase. The ligated DNA was size selected to approximately 
200bp on an E-Gel device (Invitrogen p/n G6465). The ligated DNA was nick 
8translated and amplified. After quality control, the library was hybridized to 
biotinylated cRNA oligonucleotide baits, and subsequently purified by streptavidin-
bound magnetic beads (Invitrogen p/n 656-01). The purified sample was amplified by 
ligation-mediated PCR using primers complementary to the sequence of the SOLiD 4 
full length adaptors. The enriched library was used for e-PCR based on a 
concentration of 0.5pM. A single oct of the SOLiD 4 sequencing slide (Applied 
Biosystems) was used for each sample. Average coverage 18.  
For the sequence analysis, the colour space sequence reads (50bp) were 
mapped to the human genome assembly hg19 
(ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/chromFa.tar.gz) using the 
software Bioscope 1.2.1 from Applied Biosystems (Life Technologies, Carlsbad, CA, 
USA). After mapping, the single nucleotide polymorphisms (SNPs) were identified by 
using the DiBayes algorithm (Life Technologies, Carlsbad, CA, USA) with 
mediumstringency settings. The obtained SNPs were classified into intronic, 
intergenic, coding (synonymous and non-synonymous amino acid substitutions) and 
splice-site variants with a custom software pipeline. Furthermore, all SNPs were 
compared to dbSNP build 130, OMIM and clinically relevant mutations. 
For a High-Throughput sequencing of genomic DNAs, two thousands Danish 
patients with type 1 diabetes diagnosed before the age of 16 years including affected 
sib-pair and parent-offspring families were collected and used to amplify SIRT1 exon 
1. Amplification and sequencing were performed as a fee-for-service by Microsynth 
(Balgach, CH). 
Functional analysis on human peripheral blood mononuclear cells 
Peripheral blood mononuclear cells were isolated from age matched healthy 
control, type 1 diabetes and SIRT1-L107P mutated donors using standard Ficoll 
gradient separation procedures. Aliquots of 4x104 cells were seeded in triplicate wells 
and stimulated for 48h with 5μg/mL GAD65 515-528 (Abcam #ab457240); 5μg/mL 
GAD65 protein (Abnova #H00002572-P02) or 10μg/mL insulin (Sigma #I9278). 
Enzyme Linked Immuno Spot Assay was performed using a kit from MABTECH 
(#FS-0103-2). Antigen-specific IFN-J producing cells were identified with the help of 
an AID i-spot spectrum reader. 
Alternatively, aliquots of 1x106 CD4+ Th cells from the different donors were 
stimulated (or not, for negative control) with 2ng/mL 12-O-tetradecanoylphorbol-13-
9acetate (TPA; Sigma P1585-1MG) and 2μg/mL anti-CD3 mAb (Clone SPV-T3, 
Zymed Laboratories) in 48 well plate for 24hours (for RNA isolation and gene 
expression) or overnight in the presence of Monensin (Golgi block from eBioscience 
EBIO00-4505-51), which was added 3h after the stimulation (for intracytopasmic 
cytokine staining). RNA was isolated using a RNeasy kit (QIAGEN) and gene 
expression was analyzed by one step RT-QPCR (ABI Prism 7500, Applied 
Biosystems). The following primer probe sets were purchased by Applied 
Biosystemswere run in duplicates, EF1Į was used as endogenous control to 
calculate relative gene expression. Intra Cytoplasmic staining was performed using 
FACS buffer (PBS containing 2% fetal bovine serum and 2mM EDTA), Fix/Perm and 
Permeabilization buffers from eBioscience (00-5223, 00-8333 respectively). The 
following antibodies were used: anti-FOXP3 AF488 (eBioscience 534776), anti-IL-
17A PE (eBioscience 12-7179-42), anti-CD4 PerCP (Biolegend 300527), anti-CD25 
APC (Invitrogen MHCD2505) and anti-IFNȖ PECy7 (BD 557643). Samples were 
analyzed in a FACS CANTO II (BD Biosciences). 
 
RNA extraction and real time PCR 
RNA was extracted using the NucleoSpin kit (Macherey-Nagel GmBH, 
Oensingen, Switzerland) and reverse transcribed using the SupersciptTM II Rnase H- 
reverse transcriptase kit (Invitrogen Ltd., Basel, Switzerland) and random hexamer 
primers (Microsynth, Balgach, Switzerland). Quantitative PCR was done with 
TaqMan gene expression assays and the real-time PCR system 7500 of Applied 
Biosystems.  
